MNPR
Monopar TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
ALXN1840 clinical data and a successful NDA submission could create a regulatory and commercial rerating, while the reported cash position provides meaningful development runway.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +2.3.
What can break
Commercial launch execution and demand remain unproven.
Momentum
98
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $115.00 · Bull $145.00 · Bear $75.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-19 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $114.75
Why
Momentum98 · Δ7d +2.3
Value41 · Δ7d -0.1
SentimentN/A · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
98
40% active weight
Current posture
7d trendFlat
Δ7d
+2.3
Δ21d
+15.2
Value
41
60% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 98.2 / Value 41.1
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$744.4M
Beta
1.54
Shares Out
6.7M
P/E (TTM) · Derived
-60.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-81.83
Rev YoY
-
EPS YoY
+21.4%
Gross Margin
-
Op Margin
-
Net Debt
-$140.24M
Current Ratio
56.04
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology